AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab
Asthma Drug Marketing Application Will Be Reviewed Under Standard Timelines
European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, should be fast-tracked through the EU evaluation system once the companies file for approval.
You may also be interested in...
Recently-submitted tezepelumab reduced the annualized asthma exacerbation rate by 86% in a subgroup of patients with severe, uncontrolled asthma and nasal polyps, according to data presented at the European Respiratory Society congress.
Novartis is one of the latest companies to fail in its attempt to have a marketing authorization application fast-tracked at the European Medicines Agency. There was better news for BioMarin.
Calliditas Therapeutics' lead product candidate Nefecon will be fast-tracked at the EMA once the marketing application is filed. Takeda and Bayer are hoping for the same success with maribavir and copanlisib respectively.